Aethlon Medical PE Ratio 2010-2023 | AEMD

Current and historical p/e ratio for Aethlon Medical (AEMD) from 2010 to 2023. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Aethlon Medical PE ratio as of May 22, 2024 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Aethlon Medical PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2024-05-22 0.43 0.00
2023-12-31 2.19 $-4.99 0.00
2023-09-30 2.26 $-4.82 0.00
2023-06-30 3.60 $-5.40 0.00
2023-03-31 3.83 $-6.00 0.00
2022-12-31 2.75 $-7.40 0.00
2022-09-30 5.82 $-7.80 0.00
2022-06-30 11.20 $-7.30 0.00
2022-03-31 14.60 $-7.00 0.00
2021-12-31 18.60 $-6.00 0.00
2021-09-30 38.60 $-6.40 0.00
2021-06-30 49.20 $-6.60 0.00
2021-03-31 20.30 $-6.50 0.00
2020-12-31 24.70 $-5.00 0.00
2020-09-30 13.50 $-5.80 0.00
2020-06-30 20.30 $-17.20 0.00
2020-03-31 15.20 $-32.19 0.00
2019-12-31 9.63 $-45.69 0.00
2019-09-30 34.50 $-59.38 0.00
2019-06-30 54.75 $-58.47 0.00
2019-03-31 142.50 $-50.97 0.00
2018-12-31 249.00 $-46.48 0.00
2018-09-30 177.00 $-41.98 0.00
2018-06-30 192.00 $-50.98 0.00
2018-03-31 178.50 $-73.46 0.00
2017-12-31 169.50 $-97.45 0.00
2017-09-30 231.00 $-107.95 0.00
2017-06-30 321.00 $-130.44 0.00
2017-03-31 489.86 $-140.93 0.00
2016-12-31 630.00 $-131.93 0.00
2016-09-30 753.00 $-133.43 0.00
2016-06-30 855.00 $-113.94 0.00
Sector Industry Market Cap Revenue
Medical Medical - Health Maintenance Organizations $0.001B $0.001B
Aethlon Medical, Inc. is a development stage medical device company focused on expanding the applications of our Hemopurifier (R) platform technology, which is designed to rapidly reduce the presence of infectious viruses and other toxins from human blood. In this regard, its core focus is the development of therapeutic devices that treat acute viral conditions, chronic viral diseases and pathogens targeted as potential biological warfare agents. The Hemopurifier(R) combines the established scientific principles of affinity chromatography and hemodialysis as a means to mimic the immune system's response of clearing viruses and toxins from the blood before cell and organ infection can occur. The Hemopurifier(R) cannot cure viral conditions but can prevent virus and toxins from infecting unaffected tissues and cells. The company has completed pre-clinical blood testing of the Hemopurifier(R) to treat HIV and Hepatitis-C, and have completed human safety trials on Hepatitis-C infected patients in India.
Stock Name Country Market Cap PE Ratio
UnitedHealth Group (UNH) United States $481.868B 20.32
Cigna Group (CI) United States $95.557B 12.86
Humana (HUM) United States $42.854B 14.92
Centene (CNC) United States $41.839B 11.51
Molina Healthcare (MOH) United States $20.060B 16.45
Select Medical Holdings (SEM) United States $4.452B 15.56
Joint (JYNT) United States $0.245B 233.57